Preventing Cognitive Decline with Metformin

Launched by GARVAN INSTITUTE OF MEDICAL RESEARCH · Aug 10, 2020

Keywords

ClinConnect Summary

This clinical trial, called "Preventing Cognitive Decline with Metformin," is studying whether a medication called metformin can help people with mild cognitive impairment (MCI) slow down changes in their thinking and memory over three years. MCI is a condition where individuals have noticeable issues with memory or thinking skills that are greater than expected for their age, but not severe enough to interfere significantly with daily life. The trial is not currently looking for new participants, but it is open to people aged 21 to 92 who are overweight or obese and have specific health criteria, such as normal blood sugar levels and the ability to take tests in English.

Participants in this study will receive metformin or a placebo (a pill that looks like metformin but has no active ingredient) to determine how the medication affects their cognitive abilities and brain images. To be eligible, individuals must not have any serious health issues that would prevent them from participating for the entire duration of the study, nor should they be involved in other trials related to cognitive decline. This trial aims to gather valuable information about whether metformin can be a helpful treatment for preventing cognitive decline in people who are at risk.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • overweight or obese (body mass index \>25.0 kg/m2, waist: women\>80 cm, men\>94cm;
• • Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;
• • Fasting blood glucose \<7.0 mmol/L and HbA1c \<6.5%;
• • Able to undertake neurocognitive testing in English.
• • Not participating in another trial of drugs or lifestyle modification to reduce cognitive decline.
• Exclusion Criteria:
• • Life-threatening illnesses to preclude participation in a 3-year study;
• • Contraindications to the use of metformin (severe heart failure or eGFR \<40).